P atients with atherosclerotic vascular disease who undergo noncardiac vascular surgery are at high risk for postoperative cardiac events, such as myocardial infarction and death from cardiovascular causes. Cardiac events occur in up to 24% of patients in high-risk cohorts 1 and are related to the high incidence of underlying coronary artery disease. Hertzer et al., performing routine coronary angiography in 1000 patients scheduled for vascular surgery, found that only 8% had a normal coronary-artery tree. 2 Although the pathophysiology of perioperative myocardial infarction is not entirely understood, it is well accepted that rupture of coronary plaque, leading to thrombus formation and subsequent vessel occlusion, plays an important role. The surgical stress response elicits a surge of catecholamine, with associated hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation, and consequent hypercoagulability. 3 Inflammatory processes in general and monocytederived macrophages in particular play a critical role in the progression and destabilization of coronary plaque.
Large trials involving the nonsurgical population have shown a beneficial role of long-term statin therapy on cardiac outcome. 4 These effects are related to a reduction of low-density lipoprotein (LDL) cholesterol levels and inflammation. 5 Reduction in inflammation might, independently of patients' cholesterol levels, prevent destabilization of coronary plaque induced by the stress of surgery. To our knowledge, no placebo-controlled trial has been published that assesses the effect of statins on the 30-day postoperative outcome. 6 We conducted the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography III (DECREASE III) trial to address this issue. We hypothesized that perioperative statin therapy would reduce the postoperative incidence of adverse cardiac events in patients undergoing elective vascular surgery.
Me thods
The DECREASE III trial was conducted at the Erasmus Medical Center, Rotterdam, the Netherlands. The trial was designed by the authors and approved by the medical ethics committee at Erasmus Medical Center. Novartis contributed to the support of the study. Neither Novartis nor any other organization supporting the study had a role in the design, or conduct of the trial, analysis of data, or reporting of the results. Study medication was provided by Novartis. The authors vouch for the accuracy and completeness of the data and the analyses.
Study Patients
All patients who were older than 40 years of age and were scheduled for noncardiac vascular surgery at Erasmus Medical Center from June 2004 through April 2008 were candidates for inclusion in the trial. Patients had to be scheduled for abdominal aortic aneurysm repair, distal aortoiliac reconstruction, lower-limb arterial reconstruction, or carotid-artery endarterectomy. Patients were required to have at least 51 points on a prespecified risk index that was designed for this trial (see the Supplementary Appendix, available with the full text of this article at NEJM.org). All study patients provided written informed consent.
Patients were excluded from the trial if they were currently being treated with a statin, had a contraindication for statin therapy, were undergoing surgery that could interfere with continuous 12-lead electrocardiographic (ECG) recording, were undergoing emergency surgery, were undergoing reoperation within 30 days after a previous surgical procedure, had unstable coronary artery disease, or had extensive stress-induced myocardial ischemia suggestive of left main coronary artery disease or its equivalent.
Patients who were enrolled and were already receiving long-term beta-blocker therapy continued their medication. For patients not already taking a beta-blocker, bisoprolol, at a dose of 2.5 mg once a day, was initiated at the screening visit. Betablocker therapy was adjusted as previously described for the DECREASE II study. 7
Study Treatment
Patients were randomly assigned to receive either extended-release fluvastatin (Novartis) at a dose of 80 mg, or an identical-appearing placebo, once daily. The study drug was started at the outpatient clinic on the day of randomization and was continued for at least 30 days after surgery. A computer-generated randomization list was obtained by the study statistician and given to the pharmacy department. Independent pharmacists dispensed either active study drugs or placebo according to the list. Study personnel and patients were unaware of the group assignments for the duration of the study.
Study Outcomes
The primary study outcome was the occurrence of myocardial ischemia, defined as either transient ECG signs of ischemia, release of troponin T, or both. ECG monitoring was performed using continuous ECG recording in the 48 hours after surgery and 12-lead ECG recording on days 3, 7, and 30. Troponin T measurements were performed on days 1, 3, 7, and 30. For patients who were discharged before day 7, troponin T was measured at the day of discharge.
ECG data were initially processed by a technician and analyzed by two experienced cardiologists who were unaware of the patient's clinical data. For the continuous ECG recordings, an STsegment trend was generated after excluding all abnormal QRS complexes. Episodes of ischemia were defined as periods of reversible ST-segment changes lasting at least 1 minute on continuous ECG recording and shifting from the baseline value by more than 0.1 mV (1 mm). The ST-segment change was measured 60 msec after the J point occurred, unless the J point fell within the T wave, in which case the ST-segment change was measured 40 msec after the J point occurred. Ischemia on standard 12-lead ECG recording was defined as the presence of a reversible ST-segment change, measured 60 msec after the J point occurred.
The principal secondary end point was the composite of death from cardiovascular causes and nonfatal myocardial infarction. All deaths were classified as being from either cardiovascular or noncardiovascular causes. Death from cardiovascular causes was defined as any death with a cardiovascular diagnosis as the primary or secondary cause, including death after myocardial infarction, cardiac arrhythmia, resuscitation, heart failure, or stroke. Sudden death in a previously stable patient was considered to be a death from cardiovascular causes. 8 A nonfatal myocardial infarction was diagnosed if any two of the following three criteria were present: characteristic ischemic symptoms lasting more than 20 minutes, ECG changes (new left bundle-branch block, new T-wave inversion persisting for at least 24 hours, new ST-segment depression persisting for at least 24 hours, or acute ST-segment elevation followed by appearance of Q waves or loss of R waves), or a positive troponin T level with a characteristic pattern of rising and falling values. 9 The other secondary study outcome was the effect of fluvastatin therapy on levels of biomarkers including lipids, high-sensitivity C-reactive protein, and interleukin-6. These markers were measured before initiation of the study drug and on the day of admission for the surgical procedure.
Safety outcome measures included serum creatine kinase and alanine aminotransferase levels and development of clinical myopathy and rhabdomyolysis. Blood samples were obtained before randomization, on the day of hospital admission, and on days 1, 3, 7, and 30 after surgery. The study drug was withheld if alanine aminotransferase levels were more than three times the upper limit of the normal range, if creatine kinase levels were more than 10 times the upper limit of the normal range, or if patients had myopathy or rhabdomyolysis.
Sample Size
On the basis of preliminary data from the DECREASE II registry, 7 the anticipated incidence of the primary end point, perioperative myocardial ischemia, was 18.0% in the placebo group. Treatment with fluvastatin was expected to be associated with a 50% reduction in the relative risk of the primary end point. 10, 11 We estimated that a sample of 500 patients -250 in each study group -would yield a statistical power of more than 80% to detect the anticipated 50% risk reduction associated with fluvastatin therapy, with a twosided alpha level of 0.05.
Statistical Analysis
The time to the first occurrence of the primary efficacy end point was determined according to the Kaplan-Meier method, and the difference in this time between the two groups was evaluated using the log-rank statistic. The Cox proportionalhazards model was used to determine the effects of each study drug on the primary and principal secondary efficacy end points, which are presented as hazard ratios and 95% confidence intervals. The assumption of proportional hazards was verified through visual assessment of log-minus-log survival plots. These plots demonstrated reasonably parallel lines, indicating that the proportional-hazards assumption was not violated. Analyses of other end points were based on Mann-Whitney U tests, independent-samples t-tests, and chi-square tests. Results of exploratory analyses for the primary outcome were evaluated with the use of tests for interaction of study-drug effect with baseline features. All analyses were performed according to the intention-to-treat principle. All statistical tests were two-sided, and a P value of less than 0.05 was considered to indicate statistical significance.
R e sult s

Study Subjects
Of 1669 patients assessed for trial eligibility, 1172 were excluded: 356 because they did not meet inclusion criteria, 798 because they were already taking a statin, and 18 for other reasons (see the Supplementary Appendix). Of the 497 patients who were enrolled, 250 were assigned to fluvastatin and 247 to placebo. Baseline characteristics of the patients are presented in Table 1 . The mean age was 66 years, and 74.8% of the patients were male.
The surgical procedure performed was carotidartery surgery in 69 (13.9%), abdominal aortic surgery in 236 (47.5%), and lower-limb arterial surgery in 192 (38.6%) ( Table 1 ). The median interval between initiation of the study drug and surgery was 37 days (interquartile range, 21 to 54). Between the time of randomization and the surgical procedure, no patient had an adverse cardiac outcome.
Four patients did not receive the intended study drug: three who had been assigned to fluvastatin did not take it and one who had been assigned to placebo mistakenly received preoperative statin treatment because of elevated cholesterol levels. A total of 34 patients (6.8%) discontinued the study drug because of side effects: 16 (6.4%) in the fluvastatin group and 18 (7.3%) in the placebo group (see the Supplementary Appendix). After surgery, the study drug was temporarily discontinued in 115 patients (23.1%) because of an inability to take the study drug orally.
Primary Outcome
A total of 27 of the 250 patients (10.8%) in the fluvastatin group had evidence of myocardial ischemia within 30 days after surgery, as compared with 47 of the 247 patients (19.0%) in the placebo group (hazard ratio, 0.55; 95% confidence interval [CI], 0.34 to 0.88; P = 0.01) (Fig. 1A) . Hence, the number of patients who would need to be treated to prevent 1 patient from having myocardial ischemia was 12.
Secondary Outcomes
A total of six patients receiving fluvastatin died, with four of the deaths due to cardiovascular causes. In contrast, 12 patients receiving placebo died, with 8 deaths due to cardiovascular causes. In addition, 8 patients in the fluvastatin group and 17 in the placebo group had a nonfatal myocardial infarction. The combined end point of death from cardiovascular causes or nonfatal myocardial infarction occurred in 12 of 250 patients (4.8%) receiving fluvastatin, as compared with 25 of 247 (10.1%) receiving placebo. Hence, fluvastatin therapy was associated with a 53% relative reduction in the incidence of death from cardiovascular causes or nonfatal myocardial infarction (hazard ratio, 0.47; 95% CI, 0.24 to 0.94; P = 0.03) (Fig. 1B) . The number of patients who would need to be treated to prevent the composite end point of death from cardiovascular causes or nonfatal myocardial infarction in 1 patient was 19. Baseline lipid levels were similar in the two groups (Table 2) ; 253 patients (50.9%) had a baseline total cholesterol level of less than 5.5 mmol per liter (213 mg per deciliter) and 194 patients (39.0%) had a baseline LDL cholesterol level of less than 3.0 mmol per liter (116 mg per deciliter). At the time of surgery, the mean total cholesterol and LDL cholesterol levels were reduced from the baseline levels by 1.08 mmol per liter (42 mg per deciliter) (20%) and 0.81 mmol per liter (31 mg per deciliter) (24%), respectively, in the fluvastatin group, as compared with 0.21 mmol per liter (8 mg per deciliter) (4%) and 0.10 mmol per liter (4 mg per deciliter) (3%), respectively, in the placebo group (P<0.001 for both comparisons). Changes in high-density lipoprotein cholesterol and triglyceride levels were not significant, nor did they differ significantly between the two study groups.
The median baseline high-sensitivity C-reactive protein level was 5.93 mg per liter in the fluvastatin group and 5.80 mg per liter in the placebo group (Table 2) . At the time of surgery, the median decrease in the high-sensitivity C-reactive protein level from the baseline level was 1.27 mg per liter (21%) in the fluvastatin group, whereas there was a median increase of 0.20 mg per liter (3%) in the placebo group (P<0.001). The median interleukin-6 levels at baseline were similar in the fluvastatin group (8. 
Adverse Events
The proportion of patients who had an increase in creatine kinase of more than 10 times the upper limit of the normal range was 4.0% in the fluvastatin group and 3.2% in the placebo group (Table 3) . The median peak creatine kinase level was 141 U per liter in the fluvastatin group and 113 U per liter in the placebo group (P = 0.24). The proportion of patients with an increase in alanine aminotransferase levels to more than three times the upper limit of the normal range was 3.2% in the fluvastatin group and 5.3% in the placebo group. The median peak alanine aminotransferase level was 24 U per liter in the fluvastatin group and 23 U per liter in the placebo group (P = 0.43). There were no reports of myopathy or rhabdomyolysis within 30 days after surgery in either study group.
Exploratory Findings
The relative difference in the incidence of the primary outcome, perioperative myocardial ischemia, persisted in exploratory analyses of multiple subgroups (Fig. 2) . In light of recent concerns about the safety of perioperative use of beta-blockers, we also evaluated the incidence of stroke. Three patients suffered a nonfatal postoperative stroke: two (0.8%) in the placebo group and one (0.4%) in the fluvastatin group.
Discussion
In the DECREASE III trial, we compared extendedrelease fluvastatin, at a dose of 80 mg once daily, initiated at a median of 37 days before vascular surgery, with placebo in patients who had not previously been treated with a statin and who had a mean total cholesterol level of 5.35 mmol per liter (207 mg per deciliter). We found that fluvastatin reduced the risk of perioperative myocardial ischemia. Though the trial was not powered for this end point, we also found a reduction in the risk of death from cardiovascular causes or nonfatal myocardial infarction. Fluvastatin treatment was associated with significant decreases in serum lipid levels and inflammatory activity (reflected by a reduction in high-sensitivity C-reactive protein and interleukin-6 levels).
The pathophysiology of perioperative cardiac events remains unclear. Autopsy studies suggest that approximately half of fatal myocardial infarctions in this context are attributable to a sustained mismatch between myocardial oxygen supply and demand, whereas coronary-plaque rupture is accountable for the other half. 12,13 It is thought that statins might be particularly suitable for reducing Our findings on the perioperative benefits of statins are in line with those in previous retrospective studies and one small, double-blind, randomized trial involving a total of 100 patients assigned to either 20 mg of atorvastatin, or placebo, once a day for 45 days. 17 In that trial, vascular surgery was performed, on average, 31 days after randomization. During the 6-month follow-up period, atorvastatin significantly reduced the incidence of cardiac events (8%, vs. 26% in the placebo group; P = 0.03). Though the trial was not powered to assess 30-day postoperative outcomes, there was a trend suggesting a beneficial effect of statins: three patients (6%) receiving atorvastatin had nonfatal myocardial infarction or death from cardiovascular causes, as compared with nine patients (18%) receiving placebo (odds ratio, 0.23; 95% CI, 0.09 to 1.30). Several retrospective studies have also reported a potential beneficial effect of perioperative statin use with respect to various cardiovascular outcomes, with odds ratios for active treatment ranging from 0.22 to 0.71 10, 11, 18, 19 ; the DECREASE III findings are consistent with these results. We found no heterogeneity of effect among patients in subgroups characterized by various baseline characteristics, including cardiac risk, cholesterol levels, type of surgery, and levels of inflammatory markers.
One concern with perioperative statin treatment is the necessity of treatment interruption when oral administration is not feasible during the early postoperative period. Such interruption is potentially hazardous, as sudden withdrawal of statins in the nonsurgical setting has been associated with a diminished benefit. 20, 21 In the present study, fluvastatin had to be interrupted in approximately a quarter of the patients for a median of 2 days. However, when the analysis was corrected for baseline characteristics and type of surgery, we did not find a significant increase in the rate of adverse outcomes among patients in whom fluvastatin was interrupted as compared with those who continued to receive the drug (odds ratio, 1.1; 95% CI, 0.48 to 2.52). These findings support the hypothesis that treatment with extended-release fluvastatin is robust to a gap in therapy of 1 to 2 days after surgery, when oral intake is not yet feasible. Recent guidelines from the American College of Cardiology and the American Heart Association (ACC-AHA) 22 and the TransAtlantic InterSociety Consensus on the management of peripheral arterial disease 23 indicate that statin use is appropriate in patients undergoing vascular surgery, regardless of whether they have other clinical risk factors. These guidelines are based on retrospective studies; the results of the current prospective trial confirm these recommendations.
It should also be noted that current guidelines state that long-term treatment with a statin is indicated in all patients with peripheral arterial disease. 23, 24 However, the timing of initiation of statin therapy has been a matter of debate. The clinical advisory of the ACC, AHA, and the National Heart, Lung, and Blood Institute on the use and safety of statins suggests that there is an increased risk of statin-associated myopathy during the perioperative period, indicating that "it may be prudent to withhold statins" during hospitalization for major surgery. 24 The results of the DECREASE III trial suggest that the benefits of perioperative statin use outweigh the risks and that long-term statin therapy in patients with peripheral arterial disease may be prudently initiated during the perioperative period.
In conclusion, we compared fluvastatin and placebo in patients undergoing vascular surgery. Fluvastatin therapy was associated with an im- Cardiac risk was defined as in the DECREASE II (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography II) study. 7 To convert values for cholesterol to milligrams per deciliter, divide by 0.02586. CRP denotes C-reactive protein, and LDL low-density lipoprotein.
proved postoperative cardiac outcome and a reduction in serum lipid levels and levels of markers of inflammation.
